The Latest Breaking News from Pfizer

Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June

Pfizer stock is trying to push higher on earnings but is still vulnerable. Here's the level it has to hold.

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

Pfizer stock fell Tuesday after its 2022 outlook missed overly bullish sales estimates. The company also cut its earnings view.

Pfizer Inc (NYSE:PFE) has reported a Q1 adjusted EPS of $1.62, up 72% Y/Y, well ahead of the consensus of $1.50.  The company achieved revenues of $25.66 billion, up 77%, beating the Wall Street estimate of $23.95 billion. Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues. Eliquis…

The Dow Jones Industrial Average fell Tuesday ahead of the Fed's two-day meeting. Mosaic and Pfizer were among seven key earnings movers.

New York (AFP) - Pfizer reported another quarter of huge revenues growth because of its Covid-19 vaccine on Tuesday, but lowered the company's full-year profit forecast due in part to shifts in foreign exchange.

  Pfizer (NYSE:PFE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:45 AM. Here's what investors need to know about the announcement. Earnings Pfizer beat estimated earnings by 8.0%, reporting an EPS of $1.62 versus an estimate of $1.5.

"We continue to supply the world with Comirnaty and we are on track to fulfill our commitment to deliver at least 2 billion doses to low- and middle-income countries," said CEO Albert Bourla.